Novo Nordisk and University of Washington to collaborate on exploring the role of the brain in regulating blood glucose and obesity

Novo NordiskNovo Nordisk today announced that a research collaboration has been initiated with Dr Michael Schwartz, director of The Diabetes and Obesity Center of Excellence at UW Medicine. The collaboration aims to understand factors mediating brain control of blood glucose and appetite with the ultimate goal of developing new therapeutic agents for the treatment of diabetes and obesity. The research will be conducted at UW Medicine's South Lake Union research campus in Seattle, Washington, and at Novo Nordisk.

Over the next three years, Michael W Schwartz, MD, a University of Washington professor of medicine and his team together with Novo Nordisk researchers will conduct a research programme on the effect of known hormonal factors working in the brain to regulate whole body glucose metabolism and appetite.

Dr Schwartz is a world expert in diabetes and obesity with focus on the role of the brain in the regulation of energy balance, insulin resistance and glucose metabolism. His work is continuously published in high-ranking journals and is setting direction for this field of research.

"We are very happy to enter into a close collaboration with Dr Schwartz. There is a large potential in following this angle for blood glucose and appetite control, and we hope it will bring new agents for the treatment of diabetes and obesity to the patients," says Peter Kurtzhals, senior vice president, Global Research Novo Nordisk.

Dr Michael Schwartz says, "We are excited to launch this new collaboration with colleagues at Novo Nordisk. Our collective skill and expertise will help us to both advance our understanding of the brain's role in blood sugar control and to develop novel approaches to diabetes treatment."

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries.

About UW Medicine
UW Medicine's mission is to improve the health of the public by advancing medical knowledge, providing outstanding primary and specialty care to the people of the region, and preparing tomorrow's physicians, scientists and other health professionals. UW Medicine owns or operates Harborview Medical Center, Northwest Hospital & Medical Center, Valley Medical Center, University of Washington Medical Center, a network of 10 UW Neighborhood Clinics that provide primary care and secondary care, the physician practice UW Physicians, the UW School of Medicine and Airlift Northwest. In addition, UW Medicine shares in the ownership and governance of Children's University Medical Group and Seattle Cancer Care Alliance, a partnership among UW Medicine, Fred Hutchinson Cancer Research Center and Seattle Children's. Our faculty includes 3 living Nobel Prize winners (5 in our history), 36 National Academy of Medicine members, 32 National Academy of Sciences members and 13 Howard Hughes Medical Institute investigators.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]